---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-034696"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2023-09-29T23:59:59+00:00"
generated_at: "2026-06-10T07:01:43.184192+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Anebulo appoints part-time CFO Daniel George replacing Sandra Gardiner effective Sept 28

## Summary
- Daniel George appointed part-time CFO, principal financial and accounting officer; replaces Sandra A. Gardiner.
- Compensation at $400/hour; typical schedule up to 10 hours per week, remote from Morgan Hill, CA.
- Mr. George previously CFO of Lucira Health (2020-2022) and runs a consulting practice since Dec 2022.
- Offer letter filed as Exhibit 10.1 includes standard at-will and arbitration provisions.

## SEC filing metadata
- accession: 0001493152-23-034696
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2023-09-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315223034696/0001493152-23-034696-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315223034696/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-034696
- JSON: https://secwatch.observer/filing/0001493152-23-034696.json
- Plain text: https://secwatch.observer/filing/0001493152-23-034696.txt

## Key facts
- Executive change
  Sandra A. Gardiner departed as Chief Financial Officer at Anebulo Pharmaceuticals, Inc..
  - Action: replaced
  - Role: Chief Financial Officer
  source text: On September 26, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Daniel George as the Company’s part-time Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective September 28, 2023, replacing Sandra A. Gardiner in such capacities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315223034696/0001493152-23-034696-index.htm
- Executive change
  Daniel George was appointed as part-time Chief Financial Officer at Anebulo Pharmaceuticals, Inc..
  - Action: appointed
  - Role: part-time Chief Financial Officer
  source text: On September 26, 2023, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), appointed Daniel George as the Company’s part-time Chief Financial Officer, as well as the Company’s principal financial officer and principal accounting officer, effective September 28, 2023, replacing Sandra A. Gardiner in such capacities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315223034696/0001493152-23-034696-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.